Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

被引：1

作者：

Curtis, Lauren M. ^{[1
]}

Pavletic, Steven Z. ^{[1
]}

Salit, Rachel B. ^{[1
,2
]}

Shaffer, Brian C. ^{[1
,3
]}

Steinberg, Seth M. ^{[4
]}

Wilder, Jennifer S. ^{[1
,5
]}

Pirsl, Filip ^{[1
]}

Blacklock-Schuver, Bazetta ^{[1
]}

Hsu, Jennifer ^{[1
]}

Hughes, Thomas E. ^{[6
]}

Stroncek, David ^{[7
]}

Adams, Sharon ^{[7
]}

Hendricks, Jennifer ^{[8
]}

Avila, Daniele N. ^{[1
]}

Mann, Jennifer ^{[1
]}

Halverson, David C. ^{[1
]}

Friedman, Thea M. ^{[9
]}

Korngold, Robert ^{[9
]}

Gea-Banacloche, Juan C. ^{[1
]}

Fowler, Daniel H. ^{[1
]}

Confer, Dennis L. ^{[10
]}

Hakim, Frances T. ^{[1
]}

Gress, Ronald E. ^{[1
]}

Bishop, Michael R. ^{[1
,11
]}

机构：

[1] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA

[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[3] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplant Serv, Dept Med, New York, NY 10021 USA

[4] NCI, Biostat & Data Management Sect, Bethesda, MD 20892 USA

[5] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Clin Monitoring Res Program, Frederick, MD USA

[6] NIH, Dept Pharm, Ctr Clin, Bethesda, MD 20892 USA

[7] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA

[8] NIH, Dept Social Work, Ctr Clin, Bethesda, MD 20892 USA

[9] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[10] Natl Marrow Donor Program, Minneapolis, MN USA

[11] Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation
Torlen, Johan
Ringden, Olle
Garming-Legert, Karin
Ljungman, Per
Winiarski, Jacek
Remes, Kari
Itala-Remes, Maija
Remberger, Mats
Mattsson, Jonas
HAEMATOLOGICA, 2016, 101 (11) : 1417 - 1425
[2] SIROLIMUS IN COMBINATION WITH CYCLOSPORINE OR TACROLIMUS PLUS METHOTREXATE FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION FROM UNRELATED DONORS
Furlong, T.
H.-P, Kiem
Appelbaum, F. R.
Carpenter, P. A.
Deeg, J.
Doney, K.
Flowers, M. E. D.
Mielcarek, M.
Nash, R. A.
Storh, R.
Martin, P. J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 140 - 141
[3] Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors
Furlong, Terzy
Kiem, Hans-Peter
Appelbaum, Frederick R.
Capenter, Paul A.
Deeg, H. Joachim
Doney, Kristine
Flowers, Mary E. D.
Mielcarek, Marco
Nash, Richard A.
Storb, Rainer
Martin, Paul J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (05) : 531 - 537
[4] Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
Koreth, John
Stevenson, Kristen E.
Kim, Haesook T.
Garcia, Michael
Ho, Vincent T.
Armand, Philippe
Cutler, Corey
Ritz, Jerome
Antin, Joseph H.
Soiffer, Robert J.
Alyea, Edwin P., III
BLOOD, 2009, 114 (18) : 3956 - 3959
[5] Tacrolimus/methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients who received bone marrow transplantation from unrelated donors
Jaimovich, G.
Milovic, V.
Drelichman, G.
Requejo, A.
Puente, D.
Saa, G.
Bonini, N.
Real, J.
Trentadue, J.
Feldman, L.
BONE MARROW TRANSPLANTATION, 2010, 45 : S145 - S145
[6] The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial
Armand, Philippe
Kim, Haesook T.
Sainvil, Marie-Michele
Lange, Paulina B.
Giardino, Angela A.
Bachanova, Veronika
Devine, Steven M.
Waller, Edmund K.
Jagirdar, Neera
Herrera, Alex F.
Cutler, Corey
Ho, Vincent T.
Koreth, John
Alyea, Edwin P.
McAfee, Steven L.
Soiffer, Robert J.
Chen, Yi-Bin
Antin, Joseph H.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (01) : 96 - 104
[7] Sirolimus combined with tacrolimus as graft-versus-host disease prophylaxis after allogeneic stem cell transplantation
Mattsson, J.
Svenberg, P.
Gustafsson, B.
Remberger, M.
Ringden, O.
BONE MARROW TRANSPLANTATION, 2008, 41 : S234 - S234
[8] Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Hamilton, Betty K.
Rybicki, Lisa A.
Lucas, Taylor
Corrigan, Donna
Kalaycio, Matt
Hanna, Rabi
Rotz, Seth J.
Dean, Robert M.
Gerds, Aaron T.
Hill, Brian T.
Jagadeesh, Deepa
Pohlman, Brad
Copelan, Edward A.
Majhail, Navneet S.
BLOOD, 2021, 138
[9] Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Mirza, Abu-Sayeef
Tandon, Ankita
Jenneman, Dakota
Cao, Shu
Brimer, Thomas
Kumar, Ambuj
Kidd, Michelle
Khimani, Farhad
Faramand, Rawan
Mishra, Asmita
Liu, Hien
Nishihori, Taiga
Perez, Lia
Lazaryan, Aleksandr
Bejanyan, Nelli
Nieder, Michael
Anasetti, Claudio
Pidala, Joseph
Elmariah, Hany
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (04): : 185.e1 - 185.e7
[10] Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
Alyea, Edwin P.
Li, Shuli
Kim, Haesook T.
Cutler, Corey
Ho, Vincent
Soiffer, Robert J.
Antin, Joseph H.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (08) : 920 - 926

← 1 2 3 4 5 →